Ariel Focus Fund BIO trades
Charles Bobrinskoy
Charles Bobrinskoy Bio-Rad Laboratories Inc stake
total: 59
Trades details
- Total transactions:
- 7
- New positions:
- 2
- Sold out:
- 1
- Added:
- 3
- Reduced:
- 1
- Held since:
- 2026 Q1
- Held for:
- 2 quarters
- Latest activity:
- 2026 Q2
According to 2026 Q2 report, Charles Bobrinskoy holds 5,388 Bio-Rad Laboratories Inc (BIO) shares with a market value of roughly $1.58M accounting for 1.79% of the overall portfolio. To date, the estimated cost basis is nearly $289.47 for "buy" trades. Ariel Focus Fund first purchased BIO in 2024 Q3, initially acquiring 2,522 shares. Charles Bobrinskoy later completely sold out the position and invested in Bio-Rad Laboratories Inc again in 2026 Q1. Since the initial investment in Bio-Rad Laboratories Inc (BIO), Ariel Focus Fund has made 6 more transactions.
When did Charles Bobrinskoy buy Bio-Rad Laboratories Inc (BIO)?
Charles Bobrinskoy first invested in Bio-Rad Laboratories Inc (BIO) in 2024 Q3 at the reported quarter-end price of $334.58 per share.
What's the cost basis of Ariel Focus Fund's BIO stake?
The estimated cost basis for Bio-Rad Laboratories Inc (BIO) stake is around $289.47 per share. This represents their average reported price* across all buy transactions
Estimated cost basis*
- Weighted AVG buy price:
- $289.47
Charles Bobrinskoy's historical trades in Bio-Rad Laboratories Inc
7 results
| Period |
% of portfolio |
Shares held after* |
Reported price* |
Value* |
% (shares) of activity |
% change to portfolio |
|---|---|---|---|---|---|---|
|
2026 Q2
|
1.79%
|
5,388
|
$293.61
|
$1,581,971
|
+258.72% (+3,886)
|
+1.29%
|
|
2026 Q1
|
0.52%
|
1,502
|
$278.75
|
$418,682
|
new
|
+0.52%
|
|
2025 Q3
|
0.00%
|
0
|
$241.32
|
|
-100% (-6,942)
|
-2.6%
|
|
2025 Q2
|
2.60%
|
6,942
|
$241.32
|
$1,675,243
|
-14.54% (-1,181)
|
-0.46%
|
|
2025 Q1
|
3.20%
|
8,123
|
$243.56
|
$1,978,438
|
+30.74% (+1,910)
|
+0.75%
|
|
2024 Q4
|
3.03%
|
6,213
|
$328.51
|
$2,041,033
|
+146.35% (+3,691)
|
+1.8%
|
|
2024 Q3
|
1.25%
|
2,522
|
$334.58
|
$843,811
|
new
|
+1.25%
|
* Shares, change to shares, sold shares, shares held after: split-adjusted.
* Reported price: this doesn't represent the actual buy or sell price. It is the split-adjusted price of the security as of the last day of the reported period.
If the security is completely sold out, we show the reported split-adjusted price prior to the actual period.
If the security is completely sold out, we show the reported split-adjusted price prior to the actual period.
* Estimated cost basis: based on "Reported price*" (not earlier than 2013 Q2). Calculation starts from the latest "new buy" activity to the latest "close out" activity (if any).
* Value or Price: If the security is completely sold out, we show the reported value (or price) prior to the actual period.
* New buy or own: this means there is no earlier reporting (for us or in general). So we can't know if the actual purchase of the security happened at the reported period or earlier.